Quarterly Result30 Oct 2025, 01:53 pm
Cipla Ltd Reports Highest-Ever Quarterly Revenue with Robust EBITDA Margin at 25% for Q2FY26
AI Summary
Cipla Limited, a global pharmaceutical company, announced its unaudited consolidated financial results for the quarter ended September 30, 2025. The company reported its highest-ever quarterly revenue of INR 7,589 Cr, with a robust EBITDA margin of 25%. The growth was driven by contributions across all focused markets, including One-India, North America, One Africa, and Emerging Markets and Europe. The company also maintained its leadership position in key markets and therapies.
Key Highlights
- Highest-ever quarterly revenue of INR 7,589 Cr
- Robust EBITDA margin of 25%
- Broad-based growth across all focused markets
- Launch of Filgrastim, the first biosimilar in the U.S. market
- Maintained leadership position in key markets and therapies